Skip to main navigation
Skip to search
Skip to main content
University of Canberra Research Portal Home
Search content at University of Canberra Research Portal
Home
Profiles
Research output
Projects
Press/Media
Activities
Research units
Prizes
Student theses
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn
, Sudha Rao
Health Research Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
168
Link opens in a new tab
Citations (Scopus)
57
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Epigenetics and immunotherapy: The current state of play'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Epigenetics
100%
Cancer Cells
100%
Immune Cells
100%
State of Play
100%
Tumor Microenvironment
66%
Antigen Presentation Machinery
66%
Immune Checkpoint Blockade
66%
Immune Suppression
33%
Antiviral Response
33%
Chemokines
33%
Immunogenicity
33%
Improved Outcomes
33%
Tumor Antigen
33%
Tumor Progression
33%
Immune-related Genes
33%
Immune Checkpoint Inhibitors
33%
Cancer Types
33%
Host Immune Response
33%
Immune Evasion
33%
Epigenetic Therapy
33%
Inhibitory Pathways
33%
Immunotherapeutics
33%
Epigenetic Agents
33%
Immunosurveillance
33%
Tumor Immune Escape
33%
Immune Recognition
33%
Epigenetic Drugs
33%
Ligand-receptor Interaction
33%
Cell Surface Receptor
33%
Histone Deacetylase Inhibitor (HDACi)
33%
Immunomodulation
33%
Anticancer Therapy
33%
DNA Methyltransferase 1 (DNMT1)
33%
Defense Pathways
33%
Epigenetic Modulators
33%
Programmed Death-ligand 1 (PD-L1)
33%
Immunology and Microbiology
Immunotherapy
100%
Epigenetics
100%
Immunocompetent Cell
75%
Cancer Cell
75%
Immune Checkpoint Blockade
50%
Immunomodulation
25%
Cell Surface
25%
Chemokine
25%
Immunogenicity
25%
Immune Evasion
25%
Tumor Antigen
25%
Immune System
25%
Immunosurveillance
25%
Histone
25%
Antigen Presentation
25%
Immune-Related Gene
25%
Immune Escape
25%
Programmed Death-Ligand 1
25%
Antigen Recognition
25%
Immunomodulating Drug
25%
Immune Checkpoint Inhibitor
25%